These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
647 related articles for article (PubMed ID: 23314834)
1. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834 [TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133 [TBL] [Abstract][Full Text] [Related]
3. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937 [TBL] [Abstract][Full Text] [Related]
4. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388 [No Abstract] [Full Text] [Related]
5. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Czibere A; Bruns I; Kröger N; Platzbecker U; Lind J; Zohren F; Fenk R; Germing U; Schröder T; Gräf T; Haas R; Kobbe G Bone Marrow Transplant; 2010 May; 45(5):872-6. PubMed ID: 19820729 [TBL] [Abstract][Full Text] [Related]
6. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Lübbert M; Bertz H; Wäsch R; Marks R; Rüter B; Claus R; Finke J Bone Marrow Transplant; 2010 Apr; 45(4):627-32. PubMed ID: 19718057 [TBL] [Abstract][Full Text] [Related]
9. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705 [TBL] [Abstract][Full Text] [Related]
12. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy. Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498 [TBL] [Abstract][Full Text] [Related]
13. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Graef T; Kuendgen A; Fenk R; Zohren F; Haas R; Kobbe G Leuk Res; 2007 Feb; 31(2):257-9. PubMed ID: 16620971 [TBL] [Abstract][Full Text] [Related]